These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 37670038

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer.
    Liu Z, Wang T, She Y, Wu K, Gu S, Li L, Dong C, Chen C, Zhou Y.
    Mol Cancer; 2021 Aug 20; 20(1):105. PubMed ID: 34416901
    [Abstract] [Full Text] [Related]

  • 3. NDR1 mediates PD-L1 deubiquitination to promote prostate cancer immune escape via USP10.
    Fu M, Li J, Xuan Z, Zheng Z, Liu Y, Zhang Z, Zheng J, Zhong M, Liu B, Du Y, Zhang L, Sun H.
    Cell Commun Signal; 2024 Sep 03; 22(1):429. PubMed ID: 39227807
    [Abstract] [Full Text] [Related]

  • 4. FOXP4-AS1 promotes CD8+ T cell exhaustion and esophageal cancer immune escape through USP10-stabilized PD-L1.
    Shen GY, Zhang Y, Huang RZ, Huang ZY, Yang LY, Chen DZ, Yang SB.
    Immunol Res; 2024 Aug 03; 72(4):766-775. PubMed ID: 38687433
    [Abstract] [Full Text] [Related]

  • 5. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
    Yu ZZ, Liu YY, Zhu W, Xiao D, Huang W, Lu SS, Yi H, Zeng T, Feng XP, Yuan L, Qiu JY, Wu D, Wen Q, Zhou JH, Zhuang W, Xiao ZQ.
    J Immunother Cancer; 2023 Mar 03; 11(3):. PubMed ID: 37001908
    [Abstract] [Full Text] [Related]

  • 6. The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.
    Wang Y, Sun Q, Mu N, Sun X, Wang Y, Fan S, Su L, Liu X.
    Cell Commun Signal; 2020 Jul 14; 18(1):112. PubMed ID: 32665011
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8+ T Cells in Non-Small Cell Lung Cancer.
    Li YM, Yu JM, Liu ZY, Yang HJ, Tang J, Chen ZN.
    Int J Mol Sci; 2019 Oct 17; 20(20):. PubMed ID: 31627272
    [Abstract] [Full Text] [Related]

  • 10. Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis.
    Huang Y, Xia L, Tan X, Zhang J, Zeng W, Tan B, Yu X, Fang W, Yang Z.
    Cell Mol Biol Lett; 2022 Jun 03; 27(1):43. PubMed ID: 35658874
    [Abstract] [Full Text] [Related]

  • 11. TMEM160 promotes tumor immune evasion and radiotherapy resistance via PD-L1 binding in colorectal cancer.
    Dai X, Wu Z, Ruan R, Chen J, Huang C, Lei W, Yao Y, Li L, Tang X, Xiong J, Feng M, Deng J.
    Cell Commun Signal; 2024 Mar 07; 22(1):168. PubMed ID: 38454413
    [Abstract] [Full Text] [Related]

  • 12. CXCL5 impedes CD8+ T cell immunity by upregulating PD-L1 expression in lung cancer via PXN/AKT signaling phosphorylation and neutrophil chemotaxis.
    Sun D, Tan L, Chen Y, Yuan Q, Jiang K, Liu Y, Xue Y, Zhang J, Cao X, Xu M, Luo Y, Xu Z, Xu Z, Xu W, Shen M.
    J Exp Clin Cancer Res; 2024 Jul 22; 43(1):202. PubMed ID: 39034411
    [Abstract] [Full Text] [Related]

  • 13. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H, Khanna V, Kucaba TA, Zhang W, Ferguson DM, Griffith TS, Panyam J.
    Mol Pharm; 2019 Mar 04; 16(3):1200-1210. PubMed ID: 30620878
    [Abstract] [Full Text] [Related]

  • 14. PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer.
    Wang K, Yan L, Qiu X, Chen H, Gao F, Ge W, Lian Z, Wei X, Wang S, He H, Xu X.
    Biochim Biophys Acta Mol Basis Dis; 2024 Aug 04; 1870(6):167236. PubMed ID: 38740225
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.
    Sun Z, Mai H, Xue C, Fan Z, Li J, Chen H, Huo N, Kang X, Tang C, Fang L, Zhao H, Han Y, Sun C, Peng H, Du Y, Yang J, Du N, Xu X.
    J Immunother Cancer; 2023 Dec 01; 11(12):. PubMed ID: 38040417
    [Abstract] [Full Text] [Related]

  • 18. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO, Liu W, Adeshakin FO, Afolabi LO, Zhang M, Zhang G, Wang L, Li Z, Lin L, Cao Q, Yan D, Wan X.
    Cell Immunol; 2021 Apr 01; 362():104286. PubMed ID: 33524739
    [Abstract] [Full Text] [Related]

  • 19. Chemokine C-C motif ligand 21 synergized with programmed death-ligand 1 blockade restrains tumor growth.
    Chen Q, Yin H, Pu N, Zhang J, Zhao G, Lou W, Wu W.
    Cancer Sci; 2021 Nov 01; 112(11):4457-4469. PubMed ID: 34402138
    [Abstract] [Full Text] [Related]

  • 20. EZH2 Inhibition Enhances PD-L1 Protein Stability Through USP22-Mediated Deubiquitination in Colorectal Cancer.
    Huang J, Yin Q, Wang Y, Zhou X, Guo Y, Tang Y, Cheng R, Yu X, Zhang J, Huang C, Huang Z, Zhang J, Guo Z, Huo X, Sun Y, Li Y, Wang H, Yang J, Xue L.
    Adv Sci (Weinh); 2024 Jun 01; 11(23):e2308045. PubMed ID: 38520088
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.